BioXcel Therapeutics Provides Update on the Clinical Advancement of BXCL501 for the Acute Treatment…
On Track to Initiate bXCL501 First-In-Human Pharmacokinetic (Bioavailability) and Safety Study
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a…